The University of Southampton
University of Southampton Institutional Repository

Pharmacological treatment of Generalised Anxiety Disorder

Baldwin, D.S., Ajel, K. and Garner, M. (2009) Pharmacological treatment of Generalised Anxiety Disorder In, Steckler, T. and Stein, M.B. (eds.) Behavioral Neurobiology of Anxiety and its Treatment. Springer

Record type: Book Section


Generalized anxiety disorder (GAD) is common in community and clinical settings. The individual and societal burden associated with GAD is substantial, but many of those who could benefit from treatment are not recognised or treated. Recent evidence-based guidelines for the pharmacological management of patients with GAD have recommended initial treatment with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), on the basis of their proven efficacy and reasonable tolerability in randomised placebo-controlled trials.
However, there is much room for improvement in both the efficacy and tolerability of treatment. Response rates to first-line treatment can be disappointing and it is hard to predict reliably which patients will respond well and which will have only a limited treatment response. Many patients worry about becoming dependent on medication, a substantial proportion experience troublesome adverse effects, and these problems limit the effectiveness of pharmacological treatments in clinical practice.
The relative lack of longitudinal studies of clinical outcomes in GAD and the small number of placebo-controlled relapse prevention studies lead to uncertainty about the optimal duration of treatment after a satisfactory initial response. There have been few investigations of the further management of patients who have not responded to first-line treatment and there is a pressing need for further augmentation studies, in patients who have not responded to an SSRI or SNRI, or to other initial pharmacological approaches.
Future treatment guidelines for GAD will be influenced by emerging data for established and novel pharmacological approaches, and possibly through the more accurate identification of certain patient sub-groups, that are likely to respond preferentially to particular interventions.

Full text not available from this repository.

More information

Published date: 2009


Local EPrints ID: 65050
PURE UUID: f668044b-8c0d-4997-aa3a-03853e6f1ec3

Catalogue record

Date deposited: 30 Jan 2009
Last modified: 17 Jul 2017 14:10

Export record


Author: D.S. Baldwin
Author: K. Ajel
Author: M. Garner
Editor: T. Steckler
Editor: M.B. Stein

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.